KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Evolent Health (EVH) EBITDA Margin (2016 - 2025)

Evolent Health has reported EBITDA Margin over the past 11 years, most recently at 91.61% for Q4 2025.

  • Quarterly results put EBITDA Margin at 91.61% for Q4 2025, down 8681.0% from a year ago — trailing twelve months through Dec 2025 was 30.93% (down 2725.0% YoY), and the annual figure for FY2025 was 30.93%, down 2725.0%.
  • EBITDA Margin for Q4 2025 was 91.61% at Evolent Health, down from 5.76% in the prior quarter.
  • Over the last five years, EBITDA Margin for EVH hit a ceiling of 0.53% in Q3 2022 and a floor of 91.61% in Q4 2025.
  • Median EBITDA Margin over the past 5 years was 4.91% (2024), compared with a mean of 9.51%.
  • Biggest five-year swings in EBITDA Margin: surged 8953bps in 2021 and later tumbled -8681bps in 2025.
  • Evolent Health's EBITDA Margin stood at 2.27% in 2021, then crashed by -32bps to 3.0% in 2022, then tumbled by -148bps to 7.44% in 2023, then soared by 36bps to 4.79% in 2024, then crashed by -1811bps to 91.61% in 2025.
  • The last three reported values for EBITDA Margin were 91.61% (Q4 2025), 5.76% (Q3 2025), and 11.49% (Q2 2025) per Business Quant data.